Skip to main content
Top
Published in: BMC Women's Health 1/2019

Open Access 01-12-2019 | Fertility | Research article

Norethindrone is superior to combined oral contraceptive pills in short-term delay of menses and onset of breakthrough bleeding: a randomized trial

Authors: Joshua Dean, Katherine J. Kramer, Fauzia Akbary, Shaunte Wade, Maik Hüttemann, Jay M. Berman, Maurice-Andre Recanati

Published in: BMC Women's Health | Issue 1/2019

Login to get access

Abstract

Background

To determine whether oral norethindrone acetate is superior to combined oral contraceptives (OCP) in delaying menstruation and preventing breakthrough bleeding when started late in the cycle.

Methods

This article comprises of a case control study followed by a pilot randomized controlled study. In the first study, four women who presented late in their cycle and desired avoiding vaginal bleeding within 10 days before a wedding were started on norethindrone 5 mg three times daily and compared to age matched controls started on OCPs. Subsequently, a randomized controlled pilot study (n = 50) comparing OCPs to norethindrone for the retiming of menses was conducted. Percentage of women reporting spotting were compared with level of statistical significance set at p < 0.05.

Results

Of the norethindrone treated group, only 2 women (8%) reported spotting compared with 10 women (43%) in the control group (p < 0.01). Norethindrone recipients experienced significant weight gain, which resolved after cessation of therapy and had heavier withdrawal bleed (p < 0.04) when compared to controls. Patient satisfaction was significantly higher in the norethindrone group, with 80% willing to choose this method again. Time to conceive was significantly shorter in the norethindrone group (p < 0.03).

Conclusions

Norethindrone, begun on or before cycle day 12, is superior for women who desire to avoid breakthrough bleeding and maintain fertility when compared to OCPs. It is an ideal approach in patients presenting late in their cycle and who desire delaying menses as well as in circumstances when even minute amounts of breakthrough bleeding cannot be tolerated.

Trial registration

Clinicaltrials.gov NCT03594604, July 2018. Retrospectively registered.
Literature
1.
go back to reference Fahs B, McClelland S. When Sex and Power Collide: An Argument for Critical Sexuality Studies2016. 1–25 p. Fahs B, McClelland S. When Sex and Power Collide: An Argument for Critical Sexuality Studies2016. 1–25 p.
2.
go back to reference Dandehbor W, Kazemi M, Salehi Shahrbabaki MH, Ghorashi Z, Sadrmohammad R, Bozorg B, et al. Menstrual suppression using Oral contraceptives by female hajj pilgrims. International Journal of Travel Medicine and Global Health. 2016;4(4):111–4.CrossRef Dandehbor W, Kazemi M, Salehi Shahrbabaki MH, Ghorashi Z, Sadrmohammad R, Bozorg B, et al. Menstrual suppression using Oral contraceptives by female hajj pilgrims. International Journal of Travel Medicine and Global Health. 2016;4(4):111–4.CrossRef
3.
go back to reference Mohammed-Durosinlorun A, Raji HO, Hussain NA, Badmus SA, Ijaiya MA. Menstrual suppression among female Nigerian pilgrims during hajj. The journal of family planning and reproductive health care. 2012;38(4):270–1.CrossRef Mohammed-Durosinlorun A, Raji HO, Hussain NA, Badmus SA, Ijaiya MA. Menstrual suppression among female Nigerian pilgrims during hajj. The journal of family planning and reproductive health care. 2012;38(4):270–1.CrossRef
4.
go back to reference Yairi-Oron Y, Rabinson J, Orvieto R. A simplified approach to religious infertility. Fertil Steril. 2006;86(6):1771–2.CrossRef Yairi-Oron Y, Rabinson J, Orvieto R. A simplified approach to religious infertility. Fertil Steril. 2006;86(6):1771–2.CrossRef
5.
go back to reference Ganzel T, Zimmerman D. Hormonal Intervention for Religious Concerns: A Halakhic and Ethical Discussion2011. p. 114–29. Ganzel T, Zimmerman D. Hormonal Intervention for Religious Concerns: A Halakhic and Ethical Discussion2011. p. 114–29.
6.
go back to reference Grajower MM, Willig RM, Grazi R. The Jewish Bride: Getting to Her Wedding Night Ritually Clean Using Norethindrone Acetate (Aygestin ®); 2009. p. 1–8. Grajower MM, Willig RM, Grazi R. The Jewish Bride: Getting to Her Wedding Night Ritually Clean Using Norethindrone Acetate (Aygestin ®); 2009. p. 1–8.
7.
go back to reference Lin K, Barnhart K. The clinical rationale for menses-free contraception. Journal of women's health (2002). 2007;16(8):1171–80.CrossRef Lin K, Barnhart K. The clinical rationale for menses-free contraception. Journal of women's health (2002). 2007;16(8):1171–80.CrossRef
8.
go back to reference Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52.PubMedPubMedCentral Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52.PubMedPubMedCentral
9.
go back to reference Amy JJ, Tripathi V. Contraception for women: an evidence based overview. BMJ (Clinical research ed). 2009;339:b2895.CrossRef Amy JJ, Tripathi V. Contraception for women: an evidence based overview. BMJ (Clinical research ed). 2009;339:b2895.CrossRef
10.
go back to reference Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349(15):1443–50.CrossRef Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349(15):1443–50.CrossRef
11.
go back to reference Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2016;65(3):1–103.CrossRef Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2016;65(3):1–103.CrossRef
12.
go back to reference Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception. 2016;94(3):262–74.CrossRef Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception. 2016;94(3):262–74.CrossRef
13.
go back to reference Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68(2):89–96.CrossRef Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68(2):89–96.CrossRef
14.
go back to reference Freeman S. Nondaily hormonal contraception: considerations in contraceptive choice and patient counseling. J Am Acad Nurse Pract. 2004;16(6):226–38.CrossRef Freeman S. Nondaily hormonal contraception: considerations in contraceptive choice and patient counseling. J Am Acad Nurse Pract. 2004;16(6):226–38.CrossRef
15.
go back to reference Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol. 2008;112(3):563–71.CrossRef Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol. 2008;112(3):563–71.CrossRef
16.
go back to reference Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005;106(3):473–82.CrossRef Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005;106(3):473–82.CrossRef
17.
go back to reference Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013;368(2):128–37.CrossRef Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013;368(2):128–37.CrossRef
18.
go back to reference Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient preference and adherence. 2013;7:777–85.PubMedPubMedCentral Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient preference and adherence. 2013;7:777–85.PubMedPubMedCentral
19.
go back to reference Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 1989. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 1989.
20.
go back to reference Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75(6 Suppl):S16–30.CrossRef Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75(6 Suppl):S16–30.CrossRef
21.
go back to reference Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years<sup>1</sup>. Contraception. 2002;65(2):129–32.CrossRef Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years<sup>1</sup>. Contraception. 2002;65(2):129–32.CrossRef
22.
go back to reference Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of depo-Provera. Contraception. 2004;70(1):11–8.CrossRef Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of depo-Provera. Contraception. 2004;70(1):11–8.CrossRef
23.
go back to reference Bakry S, Merhi ZO, Scalise TJ, Mahmoud M, Fadiel A, Naftolin F. Depot-medroxyprogesterone acetate: An update; 2008. p. 1–12. Bakry S, Merhi ZO, Scalise TJ, Mahmoud M, Fadiel A, Naftolin F. Depot-medroxyprogesterone acetate: An update; 2008. p. 1–12.
24.
go back to reference Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006;74(3):234–8.CrossRef Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006;74(3):234–8.CrossRef
25.
go back to reference McDaniel EB, Pardthaisong T. Return of menstruation and fertility in Thai women after contraceptive injections. J Biosoc Sci. 1971;3(2):209–22.CrossRef McDaniel EB, Pardthaisong T. Return of menstruation and fertility in Thai women after contraceptive injections. J Biosoc Sci. 1971;3(2):209–22.CrossRef
26.
go back to reference McDaniel EB, Pardthaisong T. Depot-medroxyprogesterone acetate as a contraceptive agent: return of fertility after discontinuation of use. Contraception. 1973;8(5):407–14.CrossRef McDaniel EB, Pardthaisong T. Depot-medroxyprogesterone acetate as a contraceptive agent: return of fertility after discontinuation of use. Contraception. 1973;8(5):407–14.CrossRef
27.
go back to reference Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for health and clinical excellence (NICE) clinical practice guideline. Hum Reprod. 2008;23(6):1338–45.CrossRef Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for health and clinical excellence (NICE) clinical practice guideline. Hum Reprod. 2008;23(6):1338–45.CrossRef
28.
go back to reference Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 2008;13(Suppl 1):13–28.CrossRef Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 2008;13(Suppl 1):13–28.CrossRef
29.
go back to reference Affandi B. Pregnancy after removal of Etonogestrel implant contraceptive (Implanon ®). Med J Indones. 1999;8(1):62–4.CrossRef Affandi B. Pregnancy after removal of Etonogestrel implant contraceptive (Implanon ®). Med J Indones. 1999;8(1):62–4.CrossRef
30.
go back to reference Taitel HF, Kafrissen ME. Norethindrone--a review of therapeutic applications. Int J Fertil Menopausal Stud. 1995;40(4):207–23.PubMed Taitel HF, Kafrissen ME. Norethindrone--a review of therapeutic applications. Int J Fertil Menopausal Stud. 1995;40(4):207–23.PubMed
31.
go back to reference Strobl JS. Estrogens, Progestins, and specific estrogen receptor modulators (SERMs). In: Craig CR, Stitzel RE, editors. Modern pharmacology with clinical applications. 6th ed. London: Lippincott Williams & Wilkins; 2003. p. 704–9. Strobl JS. Estrogens, Progestins, and specific estrogen receptor modulators (SERMs). In: Craig CR, Stitzel RE, editors. Modern pharmacology with clinical applications. 6th ed. London: Lippincott Williams & Wilkins; 2003. p. 704–9.
32.
go back to reference Ball MJ, Ashwell E, Gillmer MDG. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception. 1991;44(3):223–33.CrossRef Ball MJ, Ashwell E, Gillmer MDG. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception. 1991;44(3):223–33.CrossRef
33.
go back to reference Broome M, Fotherby K. Clinical experience with the progestogen-only pill. Contraception. 1990;42(5):489–95.CrossRef Broome M, Fotherby K. Clinical experience with the progestogen-only pill. Contraception. 1990;42(5):489–95.CrossRef
34.
go back to reference Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. The Cochrane database of systematic reviews. 2013;11 Cd007541. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. The Cochrane database of systematic reviews. 2013;11 Cd007541.
35.
go back to reference Dietrich JE, Srivaths L. Navigating hormones and gynecologic concerns among female adolescents in the settings of thrombophilia and anticoagulation. J Pediatr Adolesc Gynecol. 2015;28(6):549–53.CrossRef Dietrich JE, Srivaths L. Navigating hormones and gynecologic concerns among female adolescents in the settings of thrombophilia and anticoagulation. J Pediatr Adolesc Gynecol. 2015;28(6):549–53.CrossRef
36.
go back to reference Fraser IS, Weisberg E. Fertility following discontinuation of different methods of fertility control. Contraception. 1982;26(4):389–415.CrossRef Fraser IS, Weisberg E. Fertility following discontinuation of different methods of fertility control. Contraception. 1982;26(4):389–415.CrossRef
37.
go back to reference Greenblatt RB, Jungck EC. Delay of menstruation with norethindrone, an orally given progestational compound. J Am Med Assoc. 1958;166(12):1461–3.CrossRef Greenblatt RB, Jungck EC. Delay of menstruation with norethindrone, an orally given progestational compound. J Am Med Assoc. 1958;166(12):1461–3.CrossRef
Metadata
Title
Norethindrone is superior to combined oral contraceptive pills in short-term delay of menses and onset of breakthrough bleeding: a randomized trial
Authors
Joshua Dean
Katherine J. Kramer
Fauzia Akbary
Shaunte Wade
Maik Hüttemann
Jay M. Berman
Maurice-Andre Recanati
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2019
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-019-0766-6

Other articles of this Issue 1/2019

BMC Women's Health 1/2019 Go to the issue